At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Randomized, Observer-blind, Dose-finding Study to Evaluate the Immunogenicity and Safety of mRNA-based Multivalent Seasonal Influenza Vaccine Candidates in Adults 18 Years of Age and Older
In Brief
A Phase 2 clinical trial evaluating F2G22B/DL001Z, F2H23D/DL001Z-NH, and 9 other interventions for Influenza, Human. Completed, enrolled 845 participants across 18 sites.
Detailed Summary
The purpose of this study is to assess the safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent vaccine (GSK4382276A) candidate against influenza, administered in healthy younger adults (YA) and older adults (OA).
Study Details
Timeline
Interventions
Study intervention was administered intramuscularly at Day 1.
Study intervention was administered intramuscularly at Day 1.
Study intervention was administered intramuscularly at Day 1.
Study intervention was administered intramuscularly at Day 1.
Control Vaccine was administered intramuscularly at Day 1.
Study intervention was administered intramuscularly at Day 1.
Control Vaccine was administered intramuscularly at Day 1.
Study intervention was administered intramuscularly at Day 1.
Study intervention was administered intramuscularly at Day 1.
Control vaccine was administered intramuscularly at Day 1.
Control vaccine was administered intramuscularly at Day 1.